Two prominent journals at the intersection of biology and mental health have recently reported notable increases in their citation metrics, underscoring growing scientific engagement in these research domains. European Neuropsychopharmacology, a subscription-based journal with a longstanding presence, announced its Impact Factor rising significantly from 6.7 in 2024 to 8.1 in 2025. Meanwhile, Neuroscience Applied, an open-access journal launched in 2022 by the European College of Neuropsychopharmacology (ECNP), reported its inaugural Impact Factor at an impressive 3.0.
Impact Factors, a widely recognized metric in academic publishing, indicate the average frequency with which recently published articles are cited in other scholarly work. An increase typically signals enhanced relevance and influence within the scientific community. The ECNP, which owns both journals and partners with Elsevier for publication, positions itself at the forefront of applied neuroscience research, facilitating dissemination through these high-impact outlets.
Professor Eduard Vieta, Editor-in-Chief of European Neuropsychopharmacology and a leading figure at the University of Barcelona, attributes the journal’s rising prominence to strategic editorial policies designed to elevate article quality and impact. The editorial board implemented rigorous initial screening to swiftly exclude submissions unlikely to be cited, focusing on manuscripts with robust methodologies and adequate sample sizes. This deliberate tightening of selection criteria aligns with a broader surge in research exploring the biological underpinnings of psychiatric conditions, particularly within the framework of “precision psychiatry,” a field aiming to tailor interventions based on individual biological profiles.
In parallel, Neuroscience Applied’s Editor-in-Chief, Professor Andreas Meyer-Lindenberg of the University of Heidelberg and the Central Institute of Mental Health Mannheim, expressed optimism about the journal’s rapid progression. Achieving a respectable Impact Factor in its early stage reflects both effective publication strategies and a timely entry into a scientific landscape increasingly attuned to applied neuroscience. Its fully open-access model removes traditional paywall barriers, potentially accelerating visibility and citation rates as it navigates a competitive journal environment.
The significant Impact Factor boost enables European Neuropsychopharmacology to ascend into the top quartile among Psychiatry journals, ranking 13th out of 293 in its category. This success reflects a reinforcing cycle where publishing high-caliber research attracts citations, further elevating the journal’s stature and appeal to authors and readers alike.
Such developments highlight broader trends in the neuropsychiatric research community, where advances in neurobiology and methodological rigor drive burgeoning scientific interest. The emphasis on precision psychiatry—leveraging biological markers to stratify mental health disorders—mirrors a paradigm shift toward more targeted and effective therapeutic approaches, a focus mirrored by the editorial directions of these journals.
As these journals continue to attract influential research contributions, they serve as critical platforms fostering interdisciplinary dialogue between biology, neuroscience, and clinical psychiatry. Their rising Impact Factors not only represent academic metrics but also suggest a deepening engagement with pressing mental health challenges through innovative scientific inquiry.
With the ECNP hosting its annual congress in Munich in October 2026, these journals’ growing influence is expected to invigorate discussions and collaborations, further catalyzing advancements in applied neuroscience and neuropsychopharmacology.
Subject of Research: Not applicable
Keywords: Scientific publishing, Academic publishing, Science communication, Psychiatry, Neurology, Psychiatric disorders, Neurological disorders
